References
- Abe H, Kamai T (2013). Rcent advances in the treatment of metastatic renal cell carcinoma. Int J Urol, 20, 944-55.
- Anguille S, Smits EL, Bryant C, et al (2015). Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. Pharmacol Rev, 67, 731-53. https://doi.org/10.1124/pr.114.009456
- Bigot P, Lebdai S, Ravaud A, et al (2013). The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies. World J Urol, 31, 1383-8. https://doi.org/10.1007/s00345-013-1060-0
- Cao J, Huang XE, Liu J, et al (2014). Comparison of efficacy and toxicity of first line chemotherapy with or without epirubicin for patients with advanced stage soft tissue sarcoma. Asian Pac J Cancer Prev, 14, 7171-7.
- Chen R, Deng X, Wu H (2014). Combined immunotherapy with dendritic cells and cytokine-induced killer cells for malignant tumors: a systematic review and meta-analysis. Int Immunopharmacol, 22, 451-64. https://doi.org/10.1016/j.intimp.2014.07.019
- Cui L, Sun YH, Chen J, et al (2015). Analysis of Prethrombotic States in Patients with Malignant Tumors. Asian Pac J Cancer Prev, 16, 5477-82. https://doi.org/10.7314/APJCP.2015.16.13.5477
- Chodon T, Koya RC, Odunsi K (2015). Active Immunotherapy of Cancer. Immunol Invest, 44, 817-36. https://doi.org/10.3109/08820139.2015.1096684
-
Hinotsu S, Kawai K, Ozono S, et al (2013). Randomized controlled study of natural interferon
${\alpha}$ as adjuvant treatment for stage II or III renal cell carcinoma. Int J Clin Oncol, 18, 68-74. https://doi.org/10.1007/s10147-011-0345-9 - Huang XE, Tian GY, Cao J, et al (2014). Pemetrexed as a component of first-, second- and third- line chemotherapy in treating patients with metastatic lung adenocarcinoma. Asian Pac J Cancer Prev, 14, 6663-7.
- Huang XE, Yan XC, Wang L, et al (2015). Thalidomide Combined with Chemotherapy in Treating Patients with Advanced Colorectal Cancer. Asian Pac J Cancer Prev, 16, 7867-9. https://doi.org/10.7314/APJCP.2015.16.17.7867
- Huang XE, Wang L, Ji ZQ, et al (2015). Safety of Lienal Polypeptide Injection Combined with Chemotherapy in Treating Patients with Advanced Cancer. Asian Pac J Cancer Prev, 16, 7837-41. https://doi.org/10.7314/APJCP.2015.16.17.7837
- Huang XE, Cao J, Qian ZY, et al (2014). Leucogen tablets at 60 mg three times per day are safe and effective to control febrile neutropenia. Asian Pac J Cancer Prev, 15, 8495-7. https://doi.org/10.7314/APJCP.2014.15.19.8495
- Jemal A, Bray F, Center MM, et al (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90. https://doi.org/10.3322/caac.20107
- Ji ZQ, Huang XE, Wu XY, et al (2014). Safety of Brucea javanica and cantharidin combined with chemotherapy for treatment of NSCLC patients. Asian Pac J Cancer Prev, 15, 8603-5. https://doi.org/10.7314/APJCP.2014.15.20.8603
- Li Y, Huang XE (2015). A Pooled Analysis on Crizotinib in Treating Chinese Patients with -ALK Positive Non-smallcell Lung Cancer. Asian Pac J Cancer Prev, 16, 4797-800. https://doi.org/10.7314/APJCP.2015.16.11.4797
- Liu MY, Huang XE (2015). Effects of analgecine on oxaliplatininduced neurotoxicity in patients with gastrointestinal cancer. Asian Pac J Cancer Prev, 16, 4465-8. https://doi.org/10.7314/APJCP.2015.16.10.4465
- Liu J, Huang XE l (2014). Efficacy of Bifidobacterium tetragenous viable bacteria tablets for cancer patients with functional constipation. Asian Pac J Cancer Prev, 15, 10241-4.
- Liu J, Huang XE (2015). Clinical application of serum tumor abnormal protein from patients with gastric cancer. Asian Pac J Cancer Prev, 16, 4041-4. https://doi.org/10.7314/APJCP.2015.16.9.4041
- Mao Q, Li L, Zhang C, et al (2015). Clinical effects of immunotherapy of DC-CIK combined with chemotherapy in treating patients with metastatic breast cancer. Pak J Pharm Sci, 28, 1055-8.
- Schmeel FC, Schmeel LC, Gast SM, et al (2014). Adoptive immunotherapy strategies with cytokine-induced killer (CIK) cells in the treatment of hematological malignancies. Int J Mol Sci, 15, 14632-48. https://doi.org/10.3390/ijms150814632
- Wang D, Zhang B, Gao H, et al (2014). Clinical research of genetically modified dendritic cells in combination with cytokine-induced killer cell treatment in advanced renal cancer. BMC Cancer, 14, 251. https://doi.org/10.1186/1471-2407-14-251
- Wang S, Wang Z (2015). Efficacy and safety of dendritic cells cocultured with cytokine-induced killer cells immunotherapy for non-small-cell lung cancer. Int Immunopharmacol, 28, 22-8. https://doi.org/10.1016/j.intimp.2015.05.021
- Zhao X, Zhang Z, Li H, et al (2015). Cytokine induced killer cell-based immunotherapies in patients with different stages of renal cell carcinoma. Cancer Lett, 362, 192-8. https://doi.org/10.1016/j.canlet.2015.03.043